ClinicalTrials.gov recorded primary completion on 26 February 2026 for a Phase 3 trial of elranatamab in people with multiple myeloma who had received previous treatments. The study enrolled 893 participants and evaluated elranatamab alone and with daratumumab against a combination including daratumumab, pomalidomide, and dexamethasone.

Background

The trial studied elranatamab in multiple myeloma after prior treatment, including lenalidomide. The registry describes elranatamab as a BCMA-CD3 bispecific antibody. Its stated aims were to assess whether elranatamab provided more benefit than a combination therapy containing daratumumab, pomalidomide, and dexamethasone, and to evaluate elranatamab with daratumumab.

Trial design

This was a Phase 3 clinical trial involving 893 participants with multiple myeloma. The registered interventions were elranatamab, daratumumab, pomalidomide, and dexamethasone. The study examined elranatamab alone, elranatamab in combination with daratumumab, and a comparator combination including daratumumab, pomalidomide, and dexamethasone.

The registry’s brief summary states that participants had received previous treatment including lenalidomide. The study record listed the overall status as Recruiting while recording the primary-completion event on 26 February 2026.

What this means

The primary-completion entry marks a major trial milestone for elranatamab in previously treated multiple myeloma. However, the supplied record does not include primary-outcome measurements, statistical analyses, confidence intervals, p-values, or an adverse-event summary. It therefore does not establish whether elranatamab was more effective than the comparator regimen, or provide a comparative safety conclusion.

The registry entry also does not report a new approval, indication, or label change. Further interpretation will require outcome data from the trial record or a results publication.

Source

Source: ClinicalTrials.gov, trial record for NCT05020236, recording the primary-completion event on 26 February 2026. The registry record is available at clinicaltrials.gov/study/NCT05020236.